Blood Clots, Health, Health policy

Direct to consumer thrombophilia testing approved–a good thing?

On April 6, 2017, the FDA  approved marketing of 23andMe Personal Genome Service Genetic Health Risk tests for 10 diseases or conditions.(FDA Press Release 4-6-17) No prescription or physician needed. These are the first direct-to-consumer tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical conditions.  Among them, hereditary… Continue reading Direct to consumer thrombophilia testing approved–a good thing?